The proportion of patients with unfavorable mutations, such as ASXL1, RUNX1, and SETBP1, who progress to MDS/AML after HSCT, is alarmingly high, reaching 40% after 7–8 years. This evidence concerns the gene ASXL1 and myelodysplastic syndrome.